Ginkgo Bioworks (DNA) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Q1 2026 earnings are scheduled after the market close on Tuesday, May 5 (5:30 PM ET), with analysts forecasting EPS of ($1.2112) and revenue of $42.93 million.
• In the prior quarter Ginkgo reported EPS of ($1.42) which beat estimates while revenue of $33.4 million missed expectations; the company still shows negative profitability metrics (ROE -52.82%, net margin -183.81%) and a market cap of about $484 million with the stock near $7.82.
• Insiders sold sizeable positions this quarter (542,981 shares worth ~$3.55M, largely to cover tax withholding), while institutions like Millennium and State Street have increased holdings; consensus analyst sentiment is "Reduce" with an average target of $8.50.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) is anticipated to announce its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of ($1.2112) per share and revenue of $42.9280 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 5:30 PM ET.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.38. The company had revenue of $33.40 million for the quarter, compared to analyst estimates of $37.57 million. Ginkgo Bioworks had a negative return on equity of 52.82% and a negative net margin of 183.81%.

Ginkgo Bioworks Stock Performance

Shares of DNA stock opened at $7.82 on Tuesday. The stock's 50-day moving average is $7.33 and its two-hundred day moving average is $8.97. The firm has a market cap of $483.90 million, a price-to-earnings ratio of -1.38 and a beta of 1.56. Ginkgo Bioworks has a 1 year low of $5.37 and a 1 year high of $17.58.

Insiders Place Their Bets

In other Ginkgo Bioworks news, major shareholder Barry Canton sold 124,727 shares of Ginkgo Bioworks stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $6.43, for a total value of $801,994.61. Following the sale, the insider owned 436,422 shares of the company's stock, valued at approximately $2,806,193.46. The trade was a 22.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven P. Coen sold 33,171 shares of Ginkgo Bioworks stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $6.41, for a total value of $212,626.11. Following the completion of the sale, the insider directly owned 49,849 shares in the company, valued at $319,532.09. This represents a 39.96% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 542,981 shares of company stock worth $3,548,999 over the last quarter. 9.72% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of hedge funds and other institutional investors have recently modified their holdings of DNA. Millennium Management LLC lifted its position in shares of Ginkgo Bioworks by 113.1% during the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock valued at $8,137,000 after acquiring an additional 757,535 shares during the period. State Street Corp raised its position in shares of Ginkgo Bioworks by 38.4% during the 4th quarter. State Street Corp now owns 1,292,071 shares of the company's stock worth $10,737,000 after purchasing an additional 358,231 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Ginkgo Bioworks during the 4th quarter worth approximately $1,636,000. Tudor Investment Corp ET AL acquired a new position in shares of Ginkgo Bioworks during the 4th quarter worth approximately $1,612,000. Finally, Geode Capital Management LLC raised its position in shares of Ginkgo Bioworks by 23.7% during the 4th quarter. Geode Capital Management LLC now owns 999,600 shares of the company's stock worth $8,309,000 after purchasing an additional 191,240 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on DNA shares. Wall Street Zen raised Ginkgo Bioworks from a "sell" rating to a "hold" rating in a report on Saturday, April 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ginkgo Bioworks in a report on Monday, April 20th. BTIG Research lowered their price target on Ginkgo Bioworks from $9.00 to $5.00 and set a "sell" rating on the stock in a report on Thursday, March 12th. Finally, TD Cowen lowered their price target on Ginkgo Bioworks from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, January 8th. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks currently has a consensus rating of "Reduce" and an average target price of $8.50.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company's services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.